[Pilot study on clinical effects of rebamipide gargle against oral mucositis induced by fluoropyrimidines].
Gan To Kagaku Ryoho
; 38(7): 1133-6, 2011 Jul.
Article
em Ja
| MEDLINE
| ID: mdl-21772097
ABSTRACT
Rebamipide, a cytoprotective agent, has been suspected to attenuate oral mucositis through anti-inflammatory potentials and induction of endogenous prostaglandin synthesis. This prospective study was designed to assess the clinical efficacy of rebamipide gargle against oral mucositis, which is induced by fluoropyrimidines in patients with stomach and colorectal cancer. We first conducted a pilot study on gargle flavors, because the solution in this agent has a strong and bitter after taste. Nine kinds of flavors were prepared, and six characteristics were evaluated by ten volunteers sourness, bitterness, sweetness, remain, after taste, and hard to drink. We determined the contents of rebamipide using HPLC, which showed stability in an acidic condition. Finally, we decided that 100% Pokka Lemon should be used as the flavor of the rebamipide solution. A clinical study was then started to compare the preventive effects rebamipide gargle and placebo have on stomatitis, quality of life (QOL), and the therapeutic effects of chemotherapy.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Estomatite
/
Quinolonas
/
Alanina
/
Fluoruracila
/
Antissépticos Bucais
/
Antimetabólitos Antineoplásicos
Tipo de estudo:
Clinical_trials
/
Observational_studies
Limite:
Humans
Idioma:
Ja
Ano de publicação:
2011
Tipo de documento:
Article